To Assess the Contribution of Sophrology Assisted by an Ambulatory Device on the Anxiety of Patients Undergoing Chemotherapy for the Treatment of Localized Breast Cancer
3. Patient requiring chemotherapy +/- combined with immunotherapy or targeted therapy, in neoadjuvant or adjuvant seeting defined by the multidisciplinary consultation meeting.
4. Patient with signed consent
5. Patient has national health insurance coverage
You may not be if
1. Patient previously treated with chemotherapy for breast cancer
2. Patient with metastatic breast cancer
3. History of psychiatric illness or treatment with neuroleptics, antidepressants or thymoregulators thymoregulator, prior to discovery of cancer (except resolved depressive episode, without psychiatric treatment for at least 2 years). An anxiolytic or hypnotic treatment prescribed after diagnosis is authorized
4. Patient suffering from psychiatric disorders, delusional phases, schizophrenia contraindicating practice of sophrology
5. Patient who has already had an introduction to sophrology in the context of her pathology, or who plans to start sophrology within within 3 months of the start of treatment outside the hospital structure and by her own means
6. Patient does not understand or speak French
7. Cognitive impairment or inability to understand, compromising participation in the study and use and understanding of the device
8. Patient under legal protection, guardianship or trusteeship
9. Inability to undergo protocol monitoring for geographical or social reasons.
10. Patient participating in another interventional study evaluating supportive care
Clareo Health | To Assess the Contribution of Sophrology Assisted by an Ambulatory Device on the Anxiety of Patients Undergoing Chemotherapy for the Treatment of Localized Breast Cancer
